Chronic Lymphocytic Leukemia and Indolent Lymphomas (English) – Webinar Outline

Introduction: Dr. Kassouf

  • Initiation of the webinar via Zoom and some “housekeeping” points
  • Introduction of panelists
  • Acknowledgement of Lymphoma and Leukemia Society of Canada, Coalition Priorité Cancer et Association Pulmonaire du Québec
  • Present outline: presentation by Dr. Owen, testimony by Eric Pitters, live question and answer period


Part 1: Dr. Carolyn Owen

  1. Could you briefly outline the management of CLL/iNHL before the COVID-19 pandemic?
    • Diagnostic and staging methods: imaging, laboratory investigations, hospital visits. The goal here would be to highlight points of contact with the healthcare system.
    • Mention the multiple therapeutic modalities: chemotherapy, targeted therapies, monoclonal antibodies, clinical trials.
  2. How has the pandemic impacted the management of CLL/iNHL?
    • The balance between treatment benefit against the risk of exposure and immunosuppression linked to certain treatments.
      1. What are the benefits of the therapies?
        1. Which treatments are done for each stage?
        2. What is done in a medical emergency? Which treatments are prioritized? 
      2. What are the risks associated with treatment?
        1. Risks depending on the type of treatment.
      3. What are the risks linked to exposure for each treatment? Frequency of hospital visits? 
        1. Visits for injections, laboratory investigations, routine imaging?
    • Are patients with cancer at risk for increase complications with COVID-19?
      1. Do CLL/iNHL patients represent a subgroup with a different risk?
    • Practically, how does this impact our CLL/iNHL patients?
      1. Are we seeing postponement of treatments? Do postponed treatment have an impact on survival?
      2. How are urgent cases dealt with?
      3. Do we sometimes see substitutions in treatment with a more acceptable side effect profile? If so, do they have similar benefits?
      4. How do you manage side effects remotely while ensuring patient compliance?
      5. Are treatments for clinical trials still underway?
      6. Finally, how do you make the decision to start or continue treatment?
    • Overall, do you notice a gradual recovery in activities in your respective field?
      1. Are resources readily available? (medical staff, hospital beds. etc.)
      2. How does the situation at your practicing centre compare to others in the province, nationally, or internationally?
    • Any anecdotes, relevant cases you would like to share?
  3. How can patients continue to protect themselves and reduce the risk of transmission of the COVID-19 infection in healthcare settings and while interacting with healthcare professionals?
    • Comment on the measures already in place: telemedicine, PPE, screening methods when visiting hospitals


Part 2: Mr. Eric Pitters

  1. Do you feel like you are safe when receiving care?
    • Discussion over postponement of treatment and follow-up
    • Comment on your communication with healthcare workers
  2. What are your biggest fears?
  3. What activities have you adopted to deal with the current situation?
    • In terms of infection prevention
    • In terms of managing anxiety and stress
  4. What steps should healthcare professional take to ensure and maintain your confidence in these uncertain times?
  5. Any anecdotes you would like to share?


Part 3: Live Question and Answer Period


Evaluation form and acknowledgements


SEE ALL Add a note
Add your Comment
Webinars H.I.T COVID-19 © 2020 Made with ♥ by Mondien